| Parameter (adjusted to a baseline value of 100) |
Week 0 |
Week 16 |
Week 24 |
Week 52 |
|
| Platelets |
|
|
|
|
| TU/placebo |
100.0 ± 4.1 |
101.8 ± 4.5 |
103.8 ± 5.5 |
102.0 ± 5.1 |
| TU/levonorgestrel |
100.0 ± 3.7 |
104.9 ± 3.1 |
107.9 ± 3.7* |
97.2 ± 3.4 |
| TU/norethisterone-enanthate |
100.0 ± 6.1 |
102.3 ± 5.6 |
103.2 ± 5.5 |
98.3 ± 4.4 |
| Hematocrit |
|
|
|
|
| TU/placebo |
100.0 ± 1.5 |
102.2 ± 2.1 |
102.4 ± 1.3 |
99.2 ± 1.1 |
| TU/levonorgestrel |
100.0 ± 1.3 |
104.6 ± 1.7* |
104.2 ± 1.5* |
96.4 ± 0.9 |
| TU/norethisterone-enanthate |
100.0 ± 1.5 |
107.9 ± 1.2** |
108.4 ± 1.4** |
100.3 ± 1.4 |
|
 Data are given as means ± SEM. Significance levels
are shown with asterisks (* and **, representing
P values <.05 and.01, respectively) for comparison to baseline
values (post hoc test after ANOVA for repeated measurements). Values were
adjusted for comparison between groups. All values remained within normal
ranges. |
